Description of problem:
exporting a reference from Bibus in RIs format. failed

Version-Release number of selected component:
bibus-1.5.1-8.fc18

Additional info:
reporter:       libreport-2.1.4
cmdline:        python /usr/share/bibus/bibus.py
dso_list:       python-libs-2.7.3-13.fc18.i686
executable:     /usr/share/bibus/bibus.py
kernel:         3.9.4-200.fc18.i686.PAE
runlevel:       N 5
uid:            1000

Truncated backtrace:
codecs.py:351:write:UnicodeEncodeError: 'latin-1' codec can't encode character u'\u2013' in position 645: ordinal not in range(256)

Traceback (most recent call last):
  File "/usr/share/bibus/BibFrame.py", line 1135, in onMenuFileExport
    self.__FileExport( mod, enc=mod.DEFAULT_ENCODING )
  File "/usr/share/bibus/BibFrame.py", line 1121, in __FileExport
    exporter.write(ref)
  File "/usr/share/bibus/Export/RIS.py", line 57, in write
    self.infile.write(record)
  File "/usr/lib/python2.7/codecs.py", line 691, in write
    return self.writer.write(data)
  File "/usr/lib/python2.7/codecs.py", line 351, in write
    data, consumed = self.encode(object, self.errors)
UnicodeEncodeError: 'latin-1' codec can't encode character u'\u2013' in position 645: ordinal not in range(256)

Local variables in innermost frame:
self: <open file u'/home/giles/Downloads/Chen2011.ris', mode 'wb' at 0xa8bb8b8>
object: u'TY  - JOUR\nA1  - Chen, Nan\nA1  - Yu, Hai-Jin\nA1  - Zhang, Wen\nA1  - Chen, Yong-Xi\nJA  - Clin Exp Immunol\nJO  - Clinical and Experimental Immunology\nY1  - 2011//\nSP  - 52\nEP  - 3\nT1  - A randomized controlled trial of MMF versus CyP for induction therapy in ANCA-AASV with renal involvement\n\nVL  - 164 (Suppl 1)\nN2  - Objective: To compare the safety and clinical efficacies\nof MMF and intermittent CyP pulse therapy in induction\ntreatment of patients with ANCA-AASV.\nMethods: Patients with newly diagnosed AASV received\neither MMF treatment (MMF group, dose: 2.0 g/day or 1.5 g/\nday if < 50 kg) or monthly CyP pulse therapy (CyP group,\ndose: 0.5\u20130.75 g/m2/month) for 6 months. Disease activity\nwas assessed using the BVAS. The disease activity, remission\nrate, renal function, serum ANCA and adverse effects at the\n6th month were compared between the two groups.\nResults: Nineteen subjects were enrolled into the study, 10\nin the MMF group and nine in the CyP group (eight male,\n11 female, aged 61.7 \xb1 12.3 years). At diagnosis, there was no\nsignificant difference regarding BVAS, renal insufficiency\nand anaemia within the two groups. However, at the end of\nremission\u2013induction therapy, BVAS, renal insufficiency and\nanaemia was improved significantly in both groups. BVAS,\nrenal insufficiency and anaemia were improved significantly\nin the CyP group at 6 months versus at diagnosis (P = 0.001,\n0 = 0.07, P = 0.042, respectively). BVAS and renal insuffi-\nciency were improved significantly in the MMF group\nat 6 months versus at diagnosis (P = 0.01, 0 = 0.02, respec-\ntively). For side effects, pulmonary infection was not signifi-\ncantly different between the two groups (P > 0.05). However,\nmore severe infection was found in patients treated with\nMMF.\nConclusion: MMF was efficient in treating patients with\nsevere AASV. However, more severe infection was found in\npatients treated with MMF.\n'